Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

MLA

Valent, Peter, et al. “Vascular Safety Issues in CML Patients Treated with BCR/ABL1 Kinase Inhibitors.” Blood, vol. 125, no. 6, Feb. 2015, pp. 901–06. EBSCOhost, https://doi.org/10.1182/blood-2014-09-594432.

APA

Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D., Rea, D., & le Coutre, P. (2015). Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 125(6), 901–906. https://doi.org/10.1182/blood-2014-09-594432

Chicago

Valent, Peter, Emir Hadzijusufovic, Gerit-Holger Schernthaner, Dominik Wolf, Delphine Rea, and Philipp le Coutre. 2015. “Vascular Safety Issues in CML Patients Treated with BCR/ABL1 Kinase Inhibitors.” Blood 125 (6): 901–6. doi:10.1182/blood-2014-09-594432.